Highlights
1. Circulatory support escalation was required in 30% of cardiogenic shock patients, with higher mortality rates observed in these cases.
2. Escalation strategies varied, including inotropes/vasopressors, IABP, Impella, and V-A ECMO, each with distinct outcome profiles.
3. Younger age, less severe CS stages, preserved right ventricular function, and adequate urinary output predicted successful escalation.
Background
Cardiogenic shock (CS) is a life-threatening condition with high mortality rates, often requiring advanced circulatory support. Despite its critical nature, there is limited large-scale data on the outcomes of escalating circulatory support strategies. This study aims to fill that gap by analyzing a multi-center registry of CS patients.
Study Design
The study retrospectively analyzed 602 consecutive CS patients from four cardiac intensive care units. Escalation was defined as any incremental change in circulatory support after an initial bundle of care was established for at least 4 hours. The primary outcomes included hospital mortality, transition to heart replacement therapies, and complications.
Key Findings
Among the 602 patients, 30% required escalation of circulatory support. The most common escalation strategies were inotropes/vasopressors (36%), IABP (39%), Impella (14%), and V-A ECMO (11%). Escalation was associated with a significantly higher hospital mortality rate (43% vs 21%; p<0.001) and a greater transition to heart replacement therapies (23% vs 5%; p<0.001). Complications such as acute kidney injury, major bleeding, and stroke were more frequent in escalated patients, particularly those on high-profile mechanical support like Impella and V-A ECMO.
Successful discharge alive was achieved in 42% of escalated patients. Independent predictors of successful escalation included younger age, SCAI B to C stage at escalation, TAPSE at escalation, and mean urinary output ≥1 mL/kg/hour in the 6 hours preceding escalation.
Expert Commentary
The findings highlight the inherent risks associated with circulatory support escalation in CS patients. While escalation is often necessary, the choice of strategy and patient selection are critical. The study underscores the importance of assessing right ventricular function and renal perfusion before escalating support. Limitations include the retrospective design, which may introduce selection bias, and the lack of long-term follow-up data.
Conclusion
Circulatory support escalation is prevalent in CS management and is associated with higher mortality and complication rates. However, careful patient selection based on age, CS severity, and organ function can improve outcomes. Future research should focus on optimizing escalation strategies and identifying biomarkers for better patient stratification.
Funding and ClinicalTrials.gov
The study was supported by an international consortium of cardiac intensive care units. No specific funding or clinical trial registration number was provided.
References
Baldetti L, et al. Circulatory Support Escalation in Cardiogenic Shock Outcomes and Predictors of Successful Escalation from an International, Multi-Center Cardiac Intensive Care Registry. Circulation: Heart Failure. 2026.